BIO-TECHNE Corp
At today's price, BIO-TECHNE Corp (TECH) is priced for today's economics sustained for ~11.4 years. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high. Built from SEC EDGAR filings.
• Bio-Techne sells the reagents, antibodies, and assays that life-science labs consume, a razor-and-blade catalog where the Protein Sciences segment alone accounted for more than 10 percent of segment net sales across three straight fiscal years, giving the business unusually sticky, recurring demand. • The defining risk is the price: at about 43 times company-wide operating income, no valuation family, asset, earnings, peer, or forward growth, reaches today's level, so the stock is priced for r
Is TECH overvalued? See what's priced in →
566 institutional managers reported holding TECH in 13F filings for the quarter ended 2026-03-31. 59 opened new positions that quarter. Held by Vanguard Group, BlackRock, Morgan Stanley, among others. On the short side, 18.2M shares were sold short as of the 2026-06-15 count, about 12% of shares outstanding (6.2 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
TECH's share count is about flat over the past five years ($536.31M of repurchases, offset by issuance). It pays a dividend, and has paid one every year in our records (17 and counting); the current rate is $0.32 a share annually. Cash returned over the past three years: $138.24M in dividends and $355.80M in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
No open-market insider buys on file at TECH over the trailing three years. Absence is a fact about the company, not a signal. 15 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
TECH's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-08-24 | +2.1% | -21.9% |
| 2023-11-08 | -6.7% | +24.7% |
| 2024-02-08 | -6.2% | +1.2% |
| 2024-05-07 | +19.6% | -8.0% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
TECH's latest 8-K filings: 2026-06-26 (items 1.01, 5.02, 9.01); 2026-06-25 (items 7.01, 9.01); 2026-05-06 (items 2.02, 8.01, 9.01); 2026-02-11 (items 5.02, 8.01, 9.01); 2026-02-04 (items 2.02, 8.01, 9.01).
Item codes are the SEC's own classification of what each report discloses. Nothing here is investment advice.
Last analyzed: July 11, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.